Fast Weight Loss Research Articles

Weight Loss After Receiving Anti‐Obesity Medications and Gout Among Individuals With Overweight and Obese: A Population‐Based Cohort Study

ObjectiveWeight loss is conditionally recommended for gout management; however, its impact on incident gout and recurrent gout flares among individuals who were overweight and obese remains unknown. We investigate the relationship between weight loss rate following treatment with anti‐obesity medications and the risk of incident gout and recurrent gout flares among individuals who were overweight or obese.MethodsUsing data from the Health Improvement Network, we selected individuals aged 18 and older who were overweight or obese and started anti‐obesity medication. We emulated a target trial to examine the association of different weight loss rates, slow (2%–5%), moderate (5%–10%), or fast (≥10%), within the first year of treatment with incident gout and recurrent gout flares during a 5 year follow‐up period.ResultsAmong 131,000 participants without gout being treated with orlistat, the 5‐year risk of incident gout was 1.6% for those with weight gain or stability, compared with 1.5%, 1.3%, and 1.2% for those with slow, moderate, and fast weight loss, respectively. Compared with the group with weight gain or stability, the hazard ratios were 0.91 (95% confidence interval [CI] 0.81–1.01), 0.82 (95% CI 0.72–0.92), and 0.73 (95% CI 0.62–0.86) for those with a slow, moderate, and fast rate of weight loss, respectively. Similar results were observed for the recurrent gout flares among 3,847 individuals with overweight or obese with gout treated with orlistat.ConclusionA higher rate of weight loss after receiving treatment with orlistat within 1 year was associated with lower risks of incident gout and lower rates of recurrent gout flares among overweight or obese people.image

Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting

BackgroundDietary restrictions or reductions such as fasting for weight loss are often difficult to adhere to due to increased appetite and food cravings. Recently, gastrointestinal delivery of bitter hops has been shown to be effective at reducing appetite in men. Our aim was to determine the effect of a bitter hop extract on appetite and cravings in women, using a 24 h, water-only fast. MethodsThis was a randomized, double-blind, cross-over treatment study. Thirty adult women were recruited and required to fast for 24 h from 1800 h to 1800 h on three occasions and given an ad libitum meal to break each fast. Treatments of either a placebo or one of two doses (high dose; HD: 250 mg or low dose; LD: 125 mg) of a bitter hop-based appetite suppressant (Amarasate®) were given twice per day at 16 and 20 h into the fast. ResultsThe HD and LD treatment groups exhibited a significant (p < 0.05) reduction in appetite and cravings for food when compared to the placebo control. Two participants reported loose stools and one reported heartburn while on the HD treatment, and one participant reported loose stools while on the LD treatment. ConclusionThese data suggest that appetite suppressant co-therapy may be useful in reducing hunger during fasting in women and shows that gastrointestinal delivery of bitter compounds may also be an effective method of reducing cravings for food.This trial received ethical approval from the Northen B New Zealand Human Disability and Ethics committee (Northern B Health and Disability Ethics Committee (2022 EXP 10995) and was prospectively registered with the Australian New Zealand Clinical Trial Registry (ACTRN12622000107729).

Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial

COVID-19 comorbid with noncommunicable chronic diseases (NCDs) complicates the diagnosis, treatment, and prognosis, and increases the mortality rate. The aim is to evaluate the effects of a restricted diet on clinical/laboratory inflammation and metabolic profile, reactive oxygen species (ROS), and body composition in patients with COVID-19 comorbid with NCDs. We conducted a 6-week open, pilot prospective controlled clinical trial. The study included 70 adult patients with COVID-19 comorbid with type 2 diabetes (T2D), hypertension, or nonalcoholic steatohepatitis (NASH). Interventions: a restricted diet including calorie restriction, hot water drinking, walking, and sexual self-restraint. Primary endpoints: COVID-19 diagnosis by detecting SARS-CoV-2 genome by RT-PCR; weight loss in Main group; body temperature; C-reactive protein. Secondary endpoints: the number of white blood cells; erythrocyte sedimentation rate; adverse effects during treatment; fasting blood glucose, glycosylated hemoglobin A1c (HbA1c), systolic/diastolic blood pressure (BP); blood lipids; ALT/AST, chest CT-scan. In Main group, patients with overweight lost weight from baseline (− 12.4%; P < 0.0001); 2.9% in Main group and 7.2% in Controls were positive for COVID-19 (RR: 0.41, CI: 0.04–4.31; P = 0.22) on the 14th day of treatment. Body temperature and C-reactive protein decreased significantly in Main group compared to Controls on day 14th of treatment (P < 0.025). Systolic/diastolic BP normalized (P < 0.025), glucose/lipids metabolism (P < 0.025); ALT/AST normalized (P < 0.025), platelets increased from baseline (P < 0.025), chest CT (P < 0.025) in Main group at 14 day of treatment. The previous antidiabetic, antihypertensive, anti-inflammatory, hepatoprotective, and other symptomatic medications were adequately decreased to completely stop during the weight loss treatment. Thus, the fast weight loss treatment may be beneficial for the COVID-19 patients with comorbid T2D, hypertension, and NASH over traditional medical treatment because, it improved clinical and laboratory/instrumental data on inflammation; glucose/lipid metabolism, systolic/diastolic BPs, and NASH biochemical outcomes, reactive oxygen species; and allowed patients to stop taking medications.Trial Registration: ClinicalTrials.gov NCT05635539 (02/12/2022): https://clinicaltrials.gov/ct2/show/NCT05635539?term=NCT05635539&draw=2&rank=1.

Nursing Strategies for Diabetic Patient Management: Predicting Parameter Values Post-Exenatide Treatment with Machine Learning Algorithm

The global escalation of DM parallels the rise in obesity rates, with Turkey experiencing a prevalence of 13.7% for diabetes and 32% for obesity among adults. Managing diabetic patients necessitates a comprehensive approach due to the intertwined nature of diabetes and obesity, along with the heightened risk of additional chronic illnesses. Diabet nurses play a pivotal role in diabetic care, encompassing regular assessments, blood glucose monitoring, medication management, patient education. Incretin-mimetic glucagon-like peptide-1 receptor-agonists (GLP-1A) have demonstrated superiority in diabetes, weight control, positioning them as second-line treatments. Weight management remains fundamental in diabetes care, with Diabet nurses providing vital support through dietary guidance, physical activity promotion, and weight loss assistance for diabetic patients. Predicting patient responses to GLP-1A therapy is crucial for optimizing treatment outcomes, streamlining decisions, averting potential complications. Artificial intelligence (AI) and machine learning (ML) offer promising avenues for enhancing healthcare delivery. Our study aimed to forecast fasting blood sugar levels, HbA1C values, and weight loss outcomes in diabetic patients using exenatide, utilizing the random forest algorithm. Analyzing real patient data from the Western-Mediterranean, this study achieved substantial success rates of %99.9, %99.9 and %97.3 in predicting weight loss, fasting blood sugar levels, and HbA1C values, respectively. Our findings underscore the potential of AI-driven approaches in nursing, particularly in prognostic modeling for diabetic patient management. By leveraging ML, nurses can anticipate treatment responses, streamline decision-making, and elevate patient care quality. As AI applications evolve, integrating these technologies into nursing roles promises to advance patient-centered care and optimize health outcomes.

Sex Differences in Amyotrophic Lateral Sclerosis Survival and Progression: A Multidimensional Analysis.

To investigate sex-related differences in amyotrophic lateral sclerosis (ALS) prognosis and their contributing factors. Our primary cohort was the Piemonte and Aosta Register for ALS (PARALS); the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) and the Answer ALS databases were used for validation. Survival analyses were conducted accounting for age and onset site. The roles of forced vital capacity and weight decline were explored through a causal mediation analysis. Survival and disease progression rates were also evaluated after propensity score matching. The PARALS cohort included 1,890 individuals (44.8% women). Men showed shorter survival when stratified by onset site (spinal onset HR 1.20, 95% CI 1.00-1.44, p = 0.0439; bulbar onset HR 1.36, 95% CI 1.09-1.70, p = 0.006917), although women had a steeper functional decline (+0.10 ALSFRS-R points/month, 95% CI 0.07-0.15, p < 0.00001) regardless of onset site. Instead, men showed worse respiratory decline (-4.2 forced vital capacity%/month, 95% CI -6.3 to -2.2, p < 0.0001) and faster weight loss (-0.15 kg/month, 95% CI -0.25 to -0.05, p = 0.0030). Causal mediation analysis showed that respiratory function and weight loss were pivotal in sex-related survival differences. Analysis of patients from PRO-ACT (n = 1,394, 40.9% women) and Answer ALS (n = 849, 37.2% women) confirmed these trends. The shorter survival in men is linked to worse respiratory function and weight loss rather than a faster disease progression. These findings emphasize the importance of considering sex-specific factors in understanding ALS pathophysiology and designing tailored therapeutic strategies. ANN NEUROL 2024;96:159-169.

The Ketogenic Diet: The Ke(y) - to Success? A Review of Weight Loss, Lipids, and Cardiovascular Risk

Background: Obesity remains a global epidemic with over 2.8 million people dying due to complications of being overweight or obese every year. The low-carbohydrate and high-fat ketogenic diet has a rising popularity for its rapid weight loss potential. However, most studies have a maximal 2-year follow-up, and therefore long-term adverse events remain unclear including the risk of Atherosclerotic Cardiovascular Disease (ASCVD). Results: Based on current evidence on PubMed and Google Scholar, there is no strong indication ketogenic diet is advantageous for weight loss, lipid profile, and mortality. When comparing a hypocaloric ketogenic diet with a low-fat diet, there may be faster weight loss until 6 months, however, this then appears equivalent. Ketogenic diets have shown inconsistent Low-Density Lipoprotein (LDL) changes; perhaps from different saturated fat intake, dietary adherence, and genetics. Case reports have shown a 2-4-fold elevation in LDL in Familial hypercholesterolaemic patients which has mostly reversed upon dietary discontinuation. There is also concern about possible increased ASCVD and mortality: low (&lt; 40%) carbohydrate intake has been associated with increased mortality, high LDL from saturated fats, high animal product consumption can increase trimethylamine N-oxide, and cardioprotective foods are likely minimally ingested. Conclusion: Ketogenic diets have been associated with short-term positive effects including larger weight reductions. However, by 2 years there appears no significant differences for most cardiometabolic risk markers. Therefore, this raises the question, excluding those who have a critical need to lose weight fast, is this diet worth the potentially higher risks of ASCVD and mortality while further long-term studies are awaited?

Systemic proteome adaptions to 7-day complete caloric restriction in humans.

Surviving long periods without food has shaped human evolution. In ancient and modern societies, prolonged fasting was/is practiced by billions of people globally for religious purposes, used to treat diseases such as epilepsy, and recently gained popularity as weight loss intervention, but we still have a very limited understanding of the systemic adaptions in humans to extreme caloric restriction of different durations. Here we show that a 7-day water-only fast leads to an average weight loss of 5.7 kg (±0.8 kg) among 12 volunteers (5 women, 7 men). We demonstrate nine distinct proteomic response profiles, with systemic changes evident only after 3 days of complete calorie restriction based on in-depth characterization of the temporal trajectories of ~3,000 plasma proteins measured before, daily during, and after fasting. The multi-organ response to complete caloric restriction shows distinct effects of fasting duration and weight loss and is remarkably conserved across volunteers with >1,000 significantly responding proteins. The fasting signature is strongly enriched for extracellular matrix proteins from various body sites, demonstrating profound non-metabolic adaptions, including extreme changes in the brain-specific extracellular matrix protein tenascin-R. Using proteogenomic approaches, we estimate the health consequences for 212 proteins that change during fasting across ~500 outcomes and identified putative beneficial (SWAP70 and rheumatoid arthritis or HYOU1 and heart disease), as well as adverse effects. Our results advance our understanding of prolonged fasting in humans beyond a merely energy-centric adaptions towards a systemic response that can inform targeted therapeutic modulation.

Weight Loss Induced by Antiobesity Medications and All-Cause Mortality Among Patients With Knee or Hip Osteoarthritis.

The current guidelines recommend weight loss for patients with overweight or obesity and knee or hip osteoarthritis (OA); however, there is a paucity of data on the relation of weight loss to death among patients with OA. We aimed to examine the relation of the rate of weight loss induced by antiobesity medications over one year to all-cause mortality among patients with overweight or obesity and knee or hip OA. Using the IQVIA Medical Research Database, we identified people with overweight or obesity and knee or hip OA. We emulated analyses of a hypothetical target trial to assess the effect of slow-to-moderate (2%-10%) or fast (≥10%) weight loss induced by the initiation of antiobesity medications within one year on all-cause mortality and secondary outcomes over five years' follow-up. Among 6,524 participants, the five-year all-cause mortality rates were 5.3%, 4.0%, and 5.4% for weight gain or stable, slow-to-moderate weight loss, and fast weight loss arms, respectively. Compared with the weight gain or stable arm, hazard ratios of all-cause mortality were 0.72 (95% confidence interval [CI] 0.56-0.92) for the slow-to-moderate weight loss arm and 0.99 (95% CI 0.67-1.44) for the fast weight loss arm. We found dose-response protective effects of weight loss on incident hypertension, type 2 diabetes, and venous thromboembolism but a slightly higher risk of cardiovascular disease, albeit not statistically significant, in the fast rate of weight loss arm than in the weight gain or stable arm and no significant relations of weight loss to the risk of cancer. In this population-based study, a slow-to-moderate, but not fast, rate of weight loss induced by antiobesity medications is associated with a lower risk of all-cause mortality in people with overweight or obesity and knee or hip OA.

Rule Mining of Early Diabetes Symptom and Applied Supervised Machine Learning and Cross Validation Approaches based on the Most Important Features to Predict Early-stage Diabetes

Diabetes is one of several illnesses referred to be "chronic". It is the most prevalent disease that significantly impacts the population. Although there are numerous possible causes of diabetes, age, excessive body fat, frailty, fast weight loss, and many other conditions are the ones that occur most often. Diabetes patients are more susceptible to developing a number of diseases, including heart disease, kidney issues, damaged nerves, damaged blood vessels, and blindness. It is challenging to diagnose the ailment, and it is both costly and difficult to anticipate how it will develop. Machine learning (ML) offers tremendous potential to develop useful applications for earlier detection, diagnosis, and therapy, as well as the treatment of many disorders, which is why medical experts are particularly interested in it. This study aims to develop a model that can reliably and precisely identify diabetes. Following that, association rule mining was employed to find the common indications of diabetic symptoms. This study also presents a useful model for diabetes prediction that makes use of various machine-learning approaches to improve diabetes categorization and increase the precision of diabetes prediction. Machine learning methods utilized in the early stage diabetes prediction include Gaussian Naive Bayes, ExtraTreesClassifier, Decision Trees, K-Nearest Neighbors, Random Forest Classifier, Support Vector Machine, and Logistic Regression. The choice of the dataset's major attribute was then made after considering a total of six different ways. Then, a total of 10 alternative models utilized for early-stage diabetes prediction were applied to the previously selected and highlighted dataset. Accuracy, precision, recall, and F-measure are some of the metrics used to evaluate the various performance levels of these models. The performance matrices show that the ExtraTreesClassifier performed at the maximum level possible, earning a perfect score in each area with accuracy, recall, precision, and F1 score of 100%. Therefore, we can assert that the performance of our ExtraTreesClassifier model is superior to that of the already available work. Clinical doctors who read this article will gain new knowledge and be better able to identify early diabetes.

LncRNA LINC01018 Screens Type 2 Diabetes Mellitus and Regulates β Cell Function Through Modulating miR-499a-5p.

Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, which seriously endangers human health. The dysregulation of lncRNA LINC01018 in T2DM has been noticed in previous studies, but whether it served as a biomarker lacks validation. This study aimed to confirm the abnormal expression of LINC01018 in T2DM and reveals its specific function in regulating pancreatic β cell function. This study enrolled 77 T2DM patients and 41 healthy individuals and compared the plasma LINC01018 levels between two groups using PCR. The pancreatic β cell was induced with 25 mM glucose to mimic cell injury during T2DM. The effects of LINC01018 on β cell proliferation, dedifferentiation, and insulin production were evaluated by CCK8, western blotting, and ELISA. Moreover, the involvement of miR-499a-5p was also evaluated with luciferase reporter assay. Increased plasma LINC01018 was observed in T2DM patients compared with healthy individuals, which discriminates patients with high sensitivity and specificity. Upregulated LINC01018 was associated with patients' fasting blood glucose and weight loss. High glucose induced the increasing LINC01018 in pancreatic islet β cells and suppressed cell proliferation, insulin secretion, and promoted cell dedifferentiation. Silencing LINC01018 could alleviate the impaired function of β cells by high glucose, which was reversed by the knockdown by miR-499a-5p. Upregulated LINC01018 served as a potential diagnostic biomarker for T2DM and alleviated high glucose-induced β cell dysfunction via negatively modulating miR-499a-5p.

Effect of Exenatide on Nonalcoholic Steatohepatitis and Inflammation-Related Indices in Diabetic Patients with Non-Alcoholic Fatty Liver Disease.

Purpose: Diabetes mellitus is a chronic disease often associated with nonalcoholic steatohepatitis (NASH) and obesity. Both obesity and NASH are closely related to inflammation. In this study, we examined how exenatide, a glucagon-like peptide 1 analog, affects inflammatory and NASH-related markers in patients with diabetes. Methods: This retrospective study was conducted on 100 patients who visited our hospital with a diagnosis of type 2 diabetes mellitus. NASH-related indices and inflammatory indices were calculated from data obtained at baseline and at the third month of exenatide treatment. All data were analyzed first in all patients, and then the patients were grouped according to glycosylated hemoglobin A1c (HbA1c) levels of <8% or ≥8% and body mass index (BMI) of <40 or ≥40 kg/m2 and their data were reanalyzed. Results: A highly significant improvement was found in the conventional lipid profile. Among NASH-related indices, the nonalcoholic fatty liver disease (NAFLD) fibrosis score and aspartate aminotransferase-platelet ratio index (APRI) showed statistically significant decreases (P < 0.001 and P = 0.016, respectively). In particular, these significant decreases were independent of BMI and glycemic parameters. No statistically significant change was found in inflammatory indices. The decreases in NAFLD fibrosis score and APRI were statistically more significant in the group with HbA1c ≥8% (P = 0.021 and P = 0.002, respectively) and the group with BMI ≥40 kg/m2 (P = 0.002 and P = 0.029, respectively). Conclusions: Besides its established effects, such as lowering fasting plasma glucose levels and weight loss, exenatide exerts positive effects on the conventional lipid profile and NASH-associated indexes.

Differences between HbA1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia – The PREVIEW trial

To examine the differences between HbA1c and glucose related variables in predicting weight loss and glycaemic changes following 8 weeks of low energy diet (LED) in individuals with overweight and hyperglycaemia. 2178 individuals with ADA-defined pre-diabetes - impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) - who started an 8 week LED weight loss diet, were included in this analysis. Participants were enrolled in the PREVIEW (PREVention of diabetes through lifestyle interventions and population studies In Europe and around the World) clinical trial. Multivariable linear mixed effects regression models and generalised additive mixed effect logistic models were used. Only 1 in 3 participants (33%) had HbA1c levels defined as pre-diabetes. Neither baseline HbA1c, IFG or IGT were associated with body weight change at 8 weeks. Higher baseline body weight, baseline fasting insulin and weight loss predicted normalisation of fasting plasma glucose (FPG), whilst higher baseline fasting insulin, C-reactive protein (hsCRP) and older age predicted normalisation of HbA1c. Additionally, male sex and higher baseline BMI, body fat and energy intake were positively associated with weight loss, whereas greater age and higher HDL-cholesterol predicted less weight loss. Whilst neither HbA1c nor fasting glucose predicts short-term weight loss success, both may impact the metabolic response to rapid weight loss. We propose a role of inflammation versus total body adiposity since these variables are independent predictors of the normalisation of HbA1c and fasting glucose, respectively.

The Effect of Chilgoza Pine Nut (Pinus gerardiana Wall.) on Blood Glucose and Oxidative Stress in Diabetic Rat

Purpose: Diabetes can increase oxidative stress in various tissues of the body, and the progress of this process is associated with intensification of the complications of diabetes. The current study purposed to evaluate the protective effect of Pinus gerardiana (PG) seed on oxidative stress induced by diabetes in the liver and serum of streptozotocin (STZ)- induced diabetic rats. Materials and Methods: This interventional study was performed on 36 male Wistar rats. The rats were randomly divided into 6 groups (healthy controls, healthy treated with 3% and 6% (PG), diabetic control, diabetic treated with 3% and 6% (PG) doses). After 6 weeks of intervention, weight, glucose, and oxidative stress parameters in serum and liver including total antioxidant capacity, malondialdehyde, total thiol and superoxide dismutase activity were measured. Data analysis was done by statistical software version 16 and Tukey’s one-way ANOVA tests. Results: Diabetic rats showed significantly higher malondialdehyde and fasting glucose levels (12±1.2 mmol/L) and significant reductions in fasting insulin serum, weight (−37%), and activity of superoxide dismutase enzymes, total thiol groups, and total antioxidant capacity of serum and liver (about +49% in liver and +16% in serum) (p &lt; 0.001) compared with the healthy groups. Oral administration of PG nuts to diabetic rats caused a significant reduction in malondialdehyde and fasting glucose levels (−43%) and weight loss (+15%), and a significant increase in activity of superoxide dismutase enzymes, total thiol groups, and total antioxidant capacity of serum and liver (p &lt; 0.001). Conclusion: The present study concluded that PG can decrease fasting blood glucose, improve insulin resistance, reduce weight loss, and improve oxidative stress indices in the serum and liver of STZ-induced diabetic rats. It is a potential therapeutic food supplement for the treatment and prevention of hyperglycemia and high oxidative stress of diabetes.

Нутрітивний статус у хворих з раком порожнини рота та ротоглотки в предопераційному періоді

Head and neck tumors are a significant group of malignant neoplasms. Dysphagia is one of the most important problems in the nutrition of patients with tumors of the oral cavity and oropharynx. It is present in almost every patient and accounts for 90-95% of cases, both in the preoperative and postoperative period. Problems with swallowing in head and neck cancer may be related, first of all, to the type and size of the tumor itself, which disrupts the ability to eat. Disturbance in the pushing of the food lump develops as a result of dysfunction of the affected muscles or damage to peripheral nerves. There are also early and late disturbances of normal swallowing after radiation and chemotherapy for malignant tumors of the oral cavity, oropharynx, and larynx. Such patients already have a nutritional deficiency in the preoperative period. The purpose of the study was to assess the frequency of nutritional insufficiency in patients with oncology of the oral cavity and oropharynx in the preoperative period and to identify the most significant criteria for nutritional status violations. Materials and methods. The study was conducted in 41 patients, aged 38-55 years (35 men, 6 women) with stage I-III of malignant tumors of the lips, tongue, floor of the mouth and oropharynx. We determined the dynamics of weight in cancer patients with pathology of the oral cavity and oropharynx from the onset of the disease and at the stages of treatment. The patient was weighed at the time of hospitalization and in the postoperative period for 3, 5, 7, 9, 12 days. Anamnestically, weight was determined 3-6 months after the first signs of the disease. Body mass index, shoulder circumference and thickness of the skin-fatty fold of the triceps were measured and calculated, as well as laboratory indicators – biochemical markers: total protein, albumin, transferrin, absolute number of lymphocytes. Results and discussion. The patient's weight loss before the first signs of the disease averaged 6-8 kg. In the postoperative period, a gradual weight loss was noted until the ninth day after the operation, and then weight stabilization was observed. In nine days, patients lost 4-7 kg of weight from the time of hospitalization. The fastest weight loss was observed in the period of 3-7 days of the postoperative period. The average values of anthropometric indicators in the studied group, with the exception of a moderate decrease in the size of the skin-fatty fold in men, were within the normal range. A decrease in the absolute number of lymphocytes, less than 1.5 thousand in 1 μl (p &lt;0.05), was noted in 71% (29/41). Indicators characterizing the visceral protein pool (total protein, transferrin) were also within normal values, except for albumin, which was slightly reduced in 63%. Conclusion. A comprehensive study revealed in the preoperative period in patients with oncopathology of the oral cavity and oropharynx a high incidence of malnutrition (85%). The main contribution to the change of trophological status is a decrease in the cellular component of immunity and albumin

Ghost Fat: Altered Female Body Perception After Bariatric Surgery.

Body perception is an individual's ability to recognize their body in attitudinal and/or dimensional aspects. We investigated women's body perceptions before and after bariatric surgery. Participants were 31 women (M age = 36.23, SD = 7.95 years old) with an average pre-operative body mass index of 44.58 (SD = 4.65) kg/m2. We collected anthropometric and body perception measures (attitudinal body image [ABI] and dimensional body image [DBI]) before bariatric surgery and 30, 60, 90, and 120days after it. There was an average decrease of 21.09% in participants' body weight over the 120days. Regarding ABI, 51.61% of participants had high body dissatisfaction before surgery, and this proportion of dissatisfied participants decreased to 3.23% 120days after surgery. We observed no statistically significant differences in DBI perceptions. Fast weight loss caused by bariatric surgery appeared to generate a perception of ghost fat. Somatosensory interventions and/or a longer follow-up are needed to alter this persistent distortion of body dimensions.

Expert System for Diagnosing Potential Diabetes Attacks Using the Fuzzy Tsukamoto

Diabetes is one of the top three killers in Indonesia. According to the 2014 sample enrollment survey, the number of people with diabetes is increasing year by year. This is because the diagnosis of the disease is delayed. Also unhealthy lifestyle. In an era of fast and efficient technological advancement, this is a very good thing for advancement in various fields. More and more fields of knowledge are developing, one of which is expert systems. An expert system is a software or computer program that matches the ability of an expert, meaning that it can match humans with special abilities that ordinary people cannot solve. Expert systems aim to solve specific problems, such as in fields such as medicine, education, etc. This expert system takes as inputs several variables consisting of transient blood sugar (GDS), fasting blood sugar (GDP), frequent hunger, thirst, weight loss, and urine (BAK), the method used by the author is Fuzzy Tsukamoto. This Tsukamoto method states that every result of IF-Then must be described as a fuzzy set with an immutable or monotonic membership function, and uses PHP for programming. The results obtained in the study conducted by the authors were in the form of an expert system that detects diabetes and obtains results with 94% accuracy.

Processing weights of chickens determined by dual-energy X-ray absorptiometry: 1. Weight changes due to fasting, bleeding, and chilling

The increasing breast weight of modern broilers highlights the convenience of studying the dynamics of processing weights across the grow-out period. For models predicting these traits to work with non-fasted live birds under longitudinal studies, it is necessary to determine the changes in the weights of birds due to fasting and bleeding and carcasses due to chilling. This study aimed to develop a model to predict the fasting weight loss of broilers, determine the weight changes due to bleeding and chilling, and assess the percentage of gizzard fat in the abdominal fat. Models were fitted to fasting BW loss data from literature. A bleeding BW loss value obtained in a pilot study was compared to literature. This one and a single-source percent gizzard in the abdominal fat value were used as reference values. Birds from two experiments were selected at different ages to determine the following variables: non-fasted and fasted BW, bled weight, unchilled and chilled carcass weights, and gizzard fat and abdominal fat pad weights. Predicted and reference values were compared to the observed data based on their 95% confidence intervals, and the fitted model and reference values were validated if no statistical differences were inferred. The fasting BW loss model was refitted to the data from experiments, and the estimates of the model fitted to both datasets were compared. The fasting BW loss followed a three-parameter exponential model with reducing values as the bird aged, and the predicted and observed values showed no statistical difference (P > 0.05). The reference bleeding BW loss (2.76%) and gizzard fat percentage (18%) values showed no difference (P > 0.05) to data from broiler experiments, and a chilling carcass weight gain of 2.79% was determined. The scale and relative growth rate estimates of the fasting BW loss model showed no difference (P > 0.05) between datasets, and the asymptote showed a possible but negligible difference. The fasting BW loss model, the bleeding BW loss coefficient, and the gizzard fat percentage were validated. The model and coefficients obtained herein will not only be applied to predict processing weights using Dual-Energy X-ray Absorptiometry but also may be used in other modeling approaches.

A RARE CASE OF DISSEMINATED BLASTOMYCOSIS IN IMMUNOCOMPETENT PATIENT COMPLICATED BY SUPERIOR MESENTERIC ARTERY SYNDROME

TYPE: Case Report TOPIC: Chest Infections INTRODUCTION: Blastomycosis is a fungal infection, endemic to the Mississippi and Ohio River valleys. Here we report a case of disseminated blastomycosis in an immunocompetent patient with severe systemic symptoms but delayed diagnosis resulting in superior mesenteric artery syndrome (SMA) CASE PRESENTATION: A 25-year-old male presented with 3 months of intense lower back pain that progressively worsened and a 35lbs unintentional weight loss. He had been previously evaluated at an outside hospital and discharged on pain regimen with no improvement. CT Chest AP demonstrated fine miliary nodules on bilateral lungs, multiple paravertebral abscesses, osteolytic lesions throughout the axial skeleton, and most surprisingly, an incidental finding of dilation of the descending and transverse portions of the duodenum. Initial AFB smear, HIV, hepatitis, and other immunodeficiency workup was unremarkable. Patient underwent IR guided abscess aspiration of paravertebral abscess with a final culture result of BLASTOMYCES DERMATITIDIS. General Surgery was consulted due to the abnormal upper GI findings, a final diagnosis of SMA syndrome due to significant and fast weight loss from systemic disease was made. The patient ultimately required a loop duodenojejunostomy to bypass the obstruction. DISCUSSION: SMA syndrome is an uncommon cause of Upper GI obstruction, to our knowledge, this is the first case reported in association with disseminated blastomycosis. Our patient was started on Amphotericin B and later transitioned to Itraconazole long-term with marked improvement of symptoms. CONCLUSIONS: A high degree of suspicion and prompt diagnosis for blastomycosis is important, particularly in immunocompetent patients. Delayed diagnosis might represent significant morbidity such as in our patient. DISCLOSURE: Nothing to declare. KEYWORD: blastomycosis

“Belly Only Pregnancy” content on social media and in internet blogs: a qualitative analysis on its definition and potential risks and benefits

PurposeSocial media enlarge the impact of health and fitness trends on body image and lifestyle choices, also in birthing parents. A new and yet to investigate social media trend addressing expectant mothers is “Belly Only Pregnancy”. This qualitative study sought to define this new trend and clarify whether content related to this trend might disrupt body image or eating habits in expectant mothers.MethodsPicture and text data were gathered on a key day by screening Instagram and blog posts including or linking #bellyonlypregnancy. The identified data were categorized applying qualitative content analysis using MAXQDA software version 2018.ResultsThree hundred and fifty-one Instagram and eight blog posts were included. Our qualitative analysis’ results indicated that the term “Belly Only Pregnancy” was used for describing: (1) The phenotype of an athletic woman whose abdominal size enlarges during pregnancy while not gaining excessive fat tissue. (2) An active lifestyle during pregnancy consisting of healthy nutrition and regular exercise pursuing goals like fast weight loss post-partum. Also, bodily, and mental gestational changes and the feasibility of this lifestyle were discussed.ConclusionA “Belly Only Pregnancy” allegorizes an ideal body type for expecting mothers. Especially women with increased vulnerability for an eating disorder might be negatively affected by the consumption of content linked to this trend. However, the positive effects of a healthy diet and exercise should not be denied keeping into account the increasing prevalence of obesity and gestational diabetes.Level of evidenceLevel III: Evidence obtained from cohort or case-control analytic studies.

Eating disorder symptoms and their associations with anthropometric and psychiatric polygenic scores.

BackgroundEating disorder (ED) symptoms are prevalent in the general population, but their shared genetic underpinnings with psychiatric, metabolic, and anthropometric traits are not known. Here, we examined if polygenic scores (PGSs) of traits associated with anorexia nervosa are also associated with adolescent ED symptoms in the Avon Longitudinal Study of Parents and Children (ALSPAC).MethodsA total of 8654 participants with genotype data and at least one phenotypic measure were included from the ALSPAC study. We associated PGS from 25 traits (16 psychiatric, 4 metabolic, and 5 anthropometric) with eight ED symptoms, including behaviours such as fasting for weight loss and cognitions such as body dissatisfaction.ResultsHigher attention deficit hyperactivity disorder PGS and lower educational attainment PGS were associated with fasting for weight loss. Higher insomnia PGS was associated with increased body dissatisfaction. We found no evidence of an association between metabolic trait PGS and any ED symptom. Fat‐free mass, fat mass, and body fat percentage PGSs, were positively associated with binge eating, excessive exercise, fasting for weight loss, body dissatisfaction, and weight and shape concern.ConclusionsED symptoms are genetically associated with psychiatric and anthropometric, but not with metabolic traits. Our findings provide insights for future genetic research investigating on why some individuals with ED symptoms progress to develop threshold EDs while others do not.